Calliditas Therapeutics Logo

Calliditas Therapeutics

Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.

CALTX | ST

Overview

Corporate Details

ISIN(s):
SE0010441584 (+1 more)
LEI:
549300PVPZO8TNT76B58
Country:
Sweden
Address:
Box 70351, 107 24 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases (orphan indications) with significant unmet medical needs. The company's pipeline has an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide) in the U.S. and marketed as Kinpeygo® in Europe, is a novel therapeutic developed to treat primary IgA nephropathy (IgAN). Calliditas leverages its scientific and commercial expertise and seeks strategic partnerships to advance the development and global commercialization of its therapies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-16 15:30
Delisting Announcement
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
English 134.8 KB
2024-09-16 15:30
Delisting Announcement
Avnotering av Calliditas Therapeutics AB (publ) från Nasdaq Stockholm
Swedish 134.6 KB
2024-08-13 07:00
Interim Report
Swedish 2.0 MB
2024-08-13 07:00
Interim Report
English 2.0 MB
2024-08-06 11:00
Major Shareholding Notification
English 34.7 KB
2024-08-05 13:51
Major Shareholding Notification
English 34.5 KB
2024-07-31 14:00
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Calliditas Therapeutics
Swedish 180.0 KB
2024-07-31 14:00
Share Issue/Capital Change
Number of shares and votes in Calliditas Therapeutics
English 120.7 KB
2024-07-26 08:00
Earnings Release
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliar…
English 219.4 KB
2024-07-26 08:00
Regulatory News Service
Calliditas utläser positiva topline-data från fas 2b-studien TRANSFORM i primär…
Swedish 223.3 KB
2024-06-17 17:30
Post-Annual General Meeting Information
Kommuniké från årsstämman i Calliditas Therapeutics AB (publ)
Swedish 158.0 KB
2024-06-17 17:30
Post-Annual General Meeting Information
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
English 141.0 KB
2024-06-04 10:15
Major Shareholding Notification
English 34.1 KB
2024-05-30 20:00
Legal Proceedings Report
Calliditas partner STADA får positivt yttrande från CHMP som rekommenderar ett …
Swedish 176.3 KB
2024-05-30 20:00
Legal Proceedings Report
Calliditas partner STADA receives positive CHMP opinion recommending full appro…
English 177.8 KB

Automate Your Workflow. Get a real-time feed of all Calliditas Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Calliditas Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Calliditas Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-23 Diane Parks Other Other 4,086 N/A
2024-07-04 Fredrik Johansson Other Sell 36,000 7,408,800.00 SEK
2024-07-04 Fredrik Johansson Other Sell 31,439 6,476,434.00 SEK
2024-07-04 Fredrik Johansson Other Buy 40,939 N/A
2024-07-03 Frank Bringstrup Other Sell 8,000 1,646,400.00 SEK
2024-07-02 Richard Philipson Other Sell 27,209 5,591,177.41 SEK
2024-07-02 Frank Bringstrup Other Sell 9,796 2,012,980.04 SEK
2024-07-02 Sandra Boström Frithiof Other Sell 6,530 1,341,849.70 SEK
2024-07-01 Richard Philipson Other Sell 23,676 4,866,838.56 SEK
2024-07-01 Frank Bringstrup Other Sell 8,523 1,751,987.88 SEK

Peer Companies

GRI Bio, Inc. Logo
Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
United States of America
GRI
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain
GRF
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia
GRD1R
GT Biopharma, Inc. Logo
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America
GTBP
Guardant Health, Inc. Logo
Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.
United States of America
GH
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden
GUARD
Develops research antibodies and distributes scientific instruments for life science researchers.
South Korea
036180
GYRE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
United States of America
GYRE
Haleon PLC Logo
A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.
United Kingdom
HLN
Halychpharm Logo
A pharmaceutical manufacturer of finished medicines and plant-derived phytochemical substances.
Ukraine
GFARM

Talk to a Data Expert

Have a question? We'll get back to you promptly.